Bioxyne Limited (ASX:BXN)

Bioxyne Statistics

Total Valuation

Bioxyne has a market cap or net worth of AUD 91.22 million. The enterprise value is 84.78 million.

Market Cap	91.22M
Enterprise Value	84.78M

Important Dates

The last earnings date was Monday, July 28, 2025.

Earnings Date	Jul 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Bioxyne has 2.17 billion shares outstanding. The number of shares has increased by 11.33% in one year.

Current Share Class	2.17B
Shares Outstanding	2.17B
Shares Change (YoY)	+11.33%
Shares Change (QoQ)	+5.00%
Owned by Insiders (%)	51.42%
Owned by Institutions (%)	n/a
Float	602.07M

Valuation Ratios

The trailing PE ratio is 18.42.

PE Ratio	18.42
Forward PE	n/a
PS Ratio	3.00
PB Ratio	8.02
P/TBV Ratio	7.81
P/FCF Ratio	23.62
P/OCF Ratio	14.53
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.68, with an EV/FCF ratio of 21.95.

EV / Earnings	17.30
EV / Sales	2.79
EV / EBITDA	14.68
EV / EBIT	16.63
EV / FCF	21.95

Financial Position

The company has a current ratio of 2.03, with a Debt / Equity ratio of 0.13.

Current Ratio	2.03
Quick Ratio	1.22
Debt / Equity	0.13
Debt / EBITDA	0.27
Debt / FCF	0.40
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 66.79% and return on invested capital (ROIC) is 37.67%.

Return on Equity (ROE)	66.79%
Return on Assets (ROA)	23.09%
Return on Invested Capital (ROIC)	37.67%
Return on Capital Employed (ROCE)	40.96%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	2.20
Inventory Turnover	6.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +236.00% in the last 52 weeks. The beta is 0.17, so Bioxyne's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+236.00%
50-Day Moving Average	0.05
200-Day Moving Average	0.03
Relative Strength Index (RSI)	41.45
Average Volume (20 Days)	4,921,217

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bioxyne had revenue of AUD 30.42 million and earned 4.90 million in profits. Earnings per share was 0.00.

Revenue	30.42M
Gross Profit	10.45M
Operating Income	5.10M
Pretax Income	4.90M
Net Income	4.90M
EBITDA	5.34M
EBIT	5.10M
Earnings Per Share (EPS)	0.00

Balance Sheet

The company has 7.67 million in cash and 1.53 million in debt, giving a net cash position of 6.13 million or 0.00 per share.

Cash & Cash Equivalents	7.67M
Total Debt	1.53M
Net Cash	6.13M
Net Cash Per Share	0.00
Equity (Book Value)	11.38M
Book Value Per Share	0.01
Working Capital	8.69M

Cash Flow

In the last 12 months, operating cash flow was 6.28 million and capital expenditures -2.41 million, giving a free cash flow of 3.86 million.

Operating Cash Flow	6.28M
Capital Expenditures	-2.41M
Free Cash Flow	3.86M
FCF Per Share	0.00

Margins

Gross margin is 34.35%, with operating and profit margins of 16.76% and 16.11%.

Gross Margin	34.35%
Operating Margin	16.76%
Pretax Margin	16.11%
Profit Margin	16.11%
EBITDA Margin	17.56%
EBIT Margin	16.76%
FCF Margin	12.69%

Dividends & Yields

Bioxyne does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.33%
Shareholder Yield	n/a
Earnings Yield	5.37%
FCF Yield	4.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Bioxyne has an Altman Z-Score of 4.81 and a Piotroski F-Score of 6.

Altman Z-Score	4.81
Piotroski F-Score	6